Paul Tudor Jones Eagle Pharmaceuticals, Inc. Transaction History

Tudor Investment Corp Et Al

  • $26.8 Billion
  • Q3 2024

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 15, 2023
BUY
$15.21 - $22.88 $439,188 - $660,660
28,875 New
28,875 $455,000
Q4 2022

Feb 14, 2023
BUY
$24.98 - $39.77 $122,926 - $195,708
4,921 Added 17.92%
32,382 $947,000
Q3 2022

Nov 14, 2022
BUY
$26.42 - $47.12 $123,328 - $219,956
4,668 Added 20.48%
27,461 $726,000
Q2 2022

Aug 15, 2022
BUY
$41.26 - $51.35 $940,439 - $1.17 Million
22,793 New
22,793 $1.01 Million
Q1 2020

May 15, 2020
SELL
$34.37 - $60.07 $255,197 - $446,019
-7,425 Closed
0 $0
Q4 2019

Feb 14, 2020
SELL
$54.32 - $64.31 $725,334 - $858,731
-13,353 Reduced 64.27%
7,425 $446,000
Q3 2019

Nov 14, 2019
BUY
$53.25 - $59.98 $579,093 - $652,282
10,875 Added 109.82%
20,778 $1.18 Million
Q2 2019

Aug 14, 2019
SELL
$46.61 - $58.45 $91,681 - $114,971
-1,967 Reduced 16.57%
9,903 $551,000
Q1 2019

May 15, 2019
SELL
$38.66 - $51.82 $362,398 - $485,760
-9,374 Reduced 44.13%
11,870 $599,000
Q4 2018

Feb 14, 2019
BUY
$36.72 - $67.73 $318,252 - $587,015
8,667 Added 68.91%
21,244 $856,000
Q3 2018

Nov 14, 2018
BUY
$66.65 - $83.86 $569,457 - $716,499
8,544 Added 211.85%
12,577 $872,000
Q2 2018

Aug 14, 2018
BUY
$51.25 - $76.62 $206,691 - $309,008
4,033 New
4,033 $305,000

Others Institutions Holding EGRX

# of Institutions
70
Shares Held
8.6M
Call Options Held
1M
Put Options Held
100
View Full List

About EAGLE PHARMACEUTICALS, INC.

EGRX Quotes by TradingView
  • Ticker EGRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 13,015,900
  • Market Cap $7.81M
  • Description
  • Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...
More about EGRX
Track Paul Tudor Jones's Portfolio

Track Paul Tudor Jones Portfolio

Follow Paul Tudor Jones (Tudor Investment Corp Et Al) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email